A pre-commercial biotech with episodic licensing receipts and recurring cash burn
The supplied history shows no recurring product-revenue base, while operating costs have generally exceeded revenue and operating cash flow. A disclosed license payment was episodic, leaving operations dependent on external funding rather than a self-funding product business.